TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Liver fibrosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cysteine level in freshly voided urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of confirmed, adjudicated venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Behavioral activation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients completing the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expression of immune-related signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak TLC-101 drug substance concentrations (Cmax) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum TLC-101 concentration (Tmax) of drug substances in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total TLC-101 drug substance exposure (area under the curve or AUC) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (T 1/2) of TLC-101 drug substance concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in percentage of anti-gC1q compared to total anti-C1q autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in percentage of anti-cC1q compared to total anti-C1q autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline at Week 16 in Bilateral Nasal Polyp Score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline at Week 16 in Nasal Congestion Symptom Severity Score (NCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Are Lice-free
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Margin Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RP2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Event-related potential (ERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ocular itch scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent reproductive outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pediatric post intubation laryngeal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Disease Related Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive function at 1 hour after hypoxia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function at 2 hours after hypoxia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in overall postprandial BSGM Gastric Alimetry Rhythm Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Well-Being Index (WBI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants tested for HIV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose of CC-486 in combination with venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Seen by a Specialist at 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Seen by a Specialist at 12 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neuropathic Pain 4 Questions (DN4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial Cystitis Problem Index (ICPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple sleep latency test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR adjusted clinical and parasitological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in ASDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of regimen-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Distant Recurrence Free Interval (D-RFi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: American Orthopaedic Foot and Ankle Society (AOFAS) Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Function Index Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local recurrence free survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Time to invasive or noninvasive IBTR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: WisC-V (Wechsler intelligence scale for children)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: STROOP (Colors and Words Test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CARAS-R (Difference perception test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain killer consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumor imaging precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: lymphocyte and myeloid populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of positive antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sarcopenic obesity prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSA severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of occurrences for grade 3 or higher adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of pain progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new onset post-operative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seminal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejaculate volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulmonary functions (TLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in concentrations of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient's satisfactory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complication rate and types
Endpoint domain: Adverse events/effects
Primary endpoint: Prognosis of CD318 in AML
Endpoint domain: Mortality/survival
Primary endpoint: Electrolytes Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of patients with poor prognostic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Concentration of Omalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of perioperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perception of intervention adaptations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of implementation strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of the social context of the community-based health teams
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Perception of the lessons learned
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quantitative EBOV-GP-binding IgG antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in T-reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in H-reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Japanese Orthopaedics Association Scoring System for Cervical Myelopathy (mJOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Change in EEG power in alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG power in theta band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG power in gamma band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective perception of Sense of Agency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Determine maximum tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Select recommended Phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events (AEs) in Healthy Adult Subjects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events (AEs) in Adult Subjects with Psoriasis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with unsolicited immediate adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 30 days after the second and third dose in infant participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CEOAS index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Extremity Fugl-Meyer Assessment Summed Hand and Wrist Subscores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common synaptic input
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perceived Claim Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in performance accuracy of BCI use pre- and post- training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ability to use imagined movements to consistently communicate yes-no responses
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feasibility (success of using the AdaptRL model)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Study engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Self-monitoring adherence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Child's improvement in academic functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Serum estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of adverse events following tACS
Endpoint domain: Adverse events/effects
Primary endpoint: Posttraumatic Stress Disorder Checklist-Civilian Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Health Questionnaire-9
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Generalized Anxiety Disorder 7-item scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attention Bias Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention Bias Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change from baseline in absolute forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lesion-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Deployment Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: QST Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QST Pain Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shoulder Pain and Disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the interstitial cystitis symptom index (ICSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Running Related Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of IVCCI for measurement of CVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytokine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Refracture rate
Endpoint domain: Mortality/survival
Primary endpoint: Agreement between minimum luminal area measured by IVUS and OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Utah Photophobia Symptom Impact Scale (UPSIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of fatal or nonfatal ischemic stroke or peripheral emboli
Endpoint domain: Mortality/survival
Primary endpoint: Progressive change of ellipsoid zone (EZ) width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bio-burden prior to first debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bio-burden after first debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bio-burden prior to second debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV drug resistance pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quadriceps and Hamstring muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BOLD signal change during Focus>Rest contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Quality of Life scoring
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Localization efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Patients With Hemorrhage From Junctional Wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving American College of Rheumatology (ACR)50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma healthcare utilization measured by number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of complete airway closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of new cavitated caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Breath Alcohol Concentration (BrAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Carotenoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune profile evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic profile evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in frequency of lymphatic pulsing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Days requiring isolation
Endpoint domain: Adverse events/effects
Primary endpoint: GABA levels in whole stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: specific stool bacteria isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: peripheral blood immune profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax of midazolam, 1-OH Midazolam, digoxin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of midazolam, 1-OH Midazolam, digoxin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of AUC of midazolam, 1-OH midazolam, digoxin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with true-positives (sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goal Attainment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnostic performance of vibrational spectroscopy for detection of Ovarian Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminatory ability of vibrational spectroscopy to differentiate between normal, fibrotic and cancerous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean binocular BCDVA (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal bacterial community composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Adverse Events/Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pittsburgh sleep quality index (PUKI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Menopausal Symptoms Evaluation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Systemic (Non-Ocular) Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived general health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in depression and anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in psychological flexibility scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Chemotherapy-Induced Peripheral Neuropathy pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in BHB levels in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Type of oxygenation strategy adopted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal microbiome characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical symptoms evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Reported Not Following Social Distancing Guidelines
Endpoint domain: Life impact
Endpoint subdomain: Social functioning